- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04899115
VE303 for Treatment of Hepatic Encephalopathy (HE)
A Randomized Controlled Trial of VE303 to Treat Hepatic Encephalopathy
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the study drug (placebo vs.VE303). There will be visits as well as other procedures to collect blood and stool samples, and have tests of your cognition (thinking) for this research study.
The hypothesis is that VE303 will safely and effectively improve cognitive function in patients with a history of overt hepatic encephalopathy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Haila Asefa
- Phone Number: 734-232-0284
- Email: asefah@med.umich.edu
Study Contact Backup
- Name: Patricia Bloom, MD
- Phone Number: 734-647-9252
- Email: ppbloom@umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical decompensation
- History of at least one episode of overt HE any time in the past
- Prescribed both lactulose and rifaximin, and compliant with this treatment
Exclusion Criteria:
- Current episode of overt HE
- Variceal bleeding in the last 4 weeks
- Gut-absorbable or intravenous antibiotic therapy in the last 28 days
- Fecal microbiota transplant in the last 6 months
- Use of probiotics in the last 2 weeks
- Alcohol or illicit drug intake in the last 4 weeks
- Primary sclerosing cholangitis as etiology of liver disease
- History of inflammatory bowel disease, short gut, gastrointestinal tract fistulas, intestinal ischemia, or any form of ongoing colitis
- Prior diagnosis of dementia or other primary neurocognitive disorder
- Known hypersensitivity/allergy/intolerance to Vancomycin and any ingredients of VE303: sucrose, histidine, yeast extract, cysteine, metabisulfite, and microcrystalline cellulose
- History of Roux-en-Y Gastric bypass
- Any gastrointestinal surgery in the last year
- Substantial immune compromise/deficiency (e.g., uncontrolled human immunodeficiency virus, active immune suppressive therapy including high doses of corticosteroids or medications to prevent graft rejection, recent myeloablative therapy, sustained neutropenia)
- Pregnancy or breast feeding
- Model for end-stage liver disease (MELD) > 20
- History of spontaneous bacterial peritonitis
- Hemodialysis in the last 28 days
- Placement of a portosystemic shunt or transjugular intrahepatic portosystemic shunt in the last 3 months (permissible if placed >3 months before enrollment)
- Unstable doses of opiates, benzodiazepines or other sedating medication
- Chronic methadone or low dose benzodiazepines (for example) is acceptable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
|
Experimental: VE303
VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.
|
All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days. The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of serious adverse events up to week 6
Time Frame: Week 6
|
Week 6
|
|
Change in Psychometric Hepatic Encephalopathy Score (PHES) as a measure of cognitive function from pre-vancomycin to week 6
Time Frame: baseline (pre-vancomycin), Week 6
|
This score is a battery of 5 paper-pencil tests that evaluate cognitive and psychomotor processing speed and visuomotor coordination.
Scores on each subtest are assigned values based on age-related norms (1+ for scores better than 1 standard deviation (SD) above the normal mean to -3 for scores more than 3 SDs below the normal mean).
Combined scores vary from +6 to -18.
|
baseline (pre-vancomycin), Week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hospitalizations for overt hepatic encephalopathy (OHE) up to week 26
Time Frame: up to week 26
|
up to week 26
|
|
Adverse events up to week 26
Time Frame: up to week 26
|
up to week 26
|
|
Change in Patient Reported Outcome Measurement Information System (PROMIS) Global Health reported from pre-vancomycin to week 26
Time Frame: baseline (pre-vancomycin), week 26
|
The PROMIS v 1.1 is a 10 question scale where participants select answers from (0) up to (10).
Higher scores indicate better quality of life.
|
baseline (pre-vancomycin), week 26
|
Time to overt HE
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Change in microbiome composition from pre-vancomycin to week 26
Time Frame: baseline (pre-vancomycin), week 26
|
This will be calculated by beta diversity between stool collection timepoints and will have metagenomic sequencing on stool to assess this.
|
baseline (pre-vancomycin), week 26
|
Change in serum and stool biomarkers from pre-vancomycin to week 26
Time Frame: baseline (pre-vancomycin), week 26
|
baseline (pre-vancomycin), week 26
|
|
PHES from pre-vancomycin to week 26
Time Frame: pre-vancomycin up to week 26
|
This score is a battery of 5 paper-pencil tests that evaluate cognitive and psychomotor processing speed and visuomotor coordination.
Scores on each subtest are assigned values based on age-related norms (1+ for scores better than 1 standard deviation (SD) above the normal mean to -3 for scores more than 3 SDs below the normal mean).
Combined scores vary from +6 to -18.
|
pre-vancomycin up to week 26
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Patricia Bloom, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00194437
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States